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Abstract: Cutaneous melanoma (CM) is the deadliest skin cancer, whose molecular pathways
underlying its malignancy remain unclear. Therefore, new information to guide evidence-based
clinical decisions is required. Adenosine diphosphate (ADP)-ribosylation factor-like (ARL) proteins
are membrane trafficking regulators whose biological relevance in CM is undetermined. Here, we
investigated ARL expression and its impact on CM prognosis and immune microenvironment through
integrated bioinformatics analysis. Our study found that all 22 ARLs are differentially expressed
in CM. Specifically, ARL1 and ARL11 are upregulated and ARL15 is downregulated regardless
of mutational frequency or copy number variations. According to TCGA data, ARL1 and ARL15
represent independent prognostic factors in CM as well as ARL11 based on GEPIA and OncoLnc.
To investigate the mechanisms by which ARL1 and ARL11 increase patient survival while ARL15
reduces it, we evaluated their correlation with the immune microenvironment. CD4+ T cells and
neutrophil infiltrates are significantly increased by ARL1 expression. Furthermore, ARL11 expression
was correlated with 17 out of 21 immune infiltrates, including CD8+ T cells and M2 macrophages,
described as having anti-tumoral activity. Likewise, ARL11 is interconnected with ZAP70, ADAM17,
and P2RX7, which are implicated in immune cell activation. Collectively, this study provides the
first evidence that ARL1, ARL11, and ARL15 may influence CM progression, prognosis, and immune
microenvironment remodeling.
Keywords: ADP-ribosylation factor-like (ARL); small GTPases; cutaneous melanoma; biomarkers;
prognosis; immune microenvironment; metastasis; in silico study
1. Introduction
Cutaneous melanoma (CM) is the most invasive type of skin cancer, accounting for 60%
to 75% of the mortality rate related to skin neoplasms [1,2]. The dismal prognosis of this
pathology is mainly associated with its elevated metastatic potential [3]. CM often shows
the ability to metastasize even when primary lesions are thinner than 1 mm, presenting
high aggressiveness and poor prognosis [3,4]. According to the melanoma research alliance
statistics, stage IV CM is characterized by a 5-year survival rate of only 22.5% and there is
evidence showing that patients with three or more sites of metastatic disease die within
1 year [5,6]. Therefore, efforts have been made toward the early diagnosis of CM, as
early-stage CM presents a 5-year survival rate of around 90% [7].
Only in the past few years, the overall survival of CM patients has markedly improved
with the introduction of targeted therapies and immunotherapies [8–11]. Unfortunately,
treatment failures, adverse side effects, and acquired resistances represent the main causes
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of the limited success of these therapeutic approaches [12–14]. Hence, the metastatic ability
and mechanisms of resistance to therapy render the treatment of this disease challenging.
Presently, the molecular mechanisms and strategies of immune evasion essential for
CM spreading are not well understood [15]. Early identification of aggressive CM remains
one of the main goals of CM research. In this regard, the identification of new biomarkers
of prognosis and metastasis is still awaited to allow patient stratification based on disease
malignancy. Accordingly, the knowledge about the dysregulated signaling pathways
contributing to CM progression may provide important clues for the development of novel
and efficient therapies [16].
The adenosine diphosphate (ADP)-ribosylation factor (Arf) family of proteins belongs
to the Ras superfamily of small GTPases, whose members are responsible for the regulation
of essential physiological functions such as cell signaling, membrane trafficking, and
cytoskeleton reorganization [17,18]. The Arf family comprises around 30 members, namely
5 ARFs and 22 ARF-like (ARLs) proteins in humans [19]. These low-molecular-weight
proteins alternate between an inactive GDP-bound and an active GTP-bound state, working
as molecular switches that regulate trafficking and signaling networks. Several studies
have reported that ARFs can be subverted in various cancer types, influencing their
malignancy [20–22]. For instance, ARF1, ARF3, and ARF4 are upregulated in breast cancer,
promoting cell proliferation and migration [20–23]. Among ARF proteins, only ARF6 was
described as having an essential role in early and late stages of CM metastasis, mediated
by the activation of mitogen-activated protein kinase (MAPK) and phosphatidylinositol
3-kinase (PI3K)/protein kinase B(Akt) signaling pathways [24,25].
In contrast to Arf proteins, the biochemical and functional characterization of Arls
under physiological and pathological conditions is poorly explored [26]. The physiological
functions of most Arls are still unclear. Available data demonstrate that these proteins are
involved in a multiplicity of functions. For instance, Arl1 is recruited to the trans-Golgi
network being involved in multiple processes such as cargo transport, cell polarity, innate
immunity, and secretion of insulin and matrix metalloproteinases [27]. Arl13b interacts
with actin and it is also a regulator of ciliogenesis [28]. Furthermore, a recent study
proposed that ARL11 is required for macrophage activation and immune function [29],
and ARL15 has been described as having an important role in adipocyte differentiation
and adiponectin secretion [30]. It is also known that ARL2 is a tumor suppressor gene in
breast and pancreatic cancer, but in cervical and bladder cancer its suppression is related
to a significant decrease in cell proliferation, migration, and invasion [31–33]. ARL4C
overexpression was reported as a prognostic factor of poor outcome in colorectal cancer
and suggested as an important stimulator of cell proliferation and migration in several
types of cancer [34,35]. Furthermore, ARL8B knockdown abrogates the growth of prostate
tumors in mice [36], as well as decreases invasive tumor growth and distant metastasis
of breast tumors in a mouse xenograft model [37] and ARL5A downregulation reduces
colorectal cancer proliferation [38]. ARL13B, one of the most studied proteins from this
family, was implicated in tumorigenesis and progression of medulloblastoma [39] and
gastric [40] and breast [41] cancers. Indeed, our group has been focused on the study of
ARLs for a long time, namely on the effect of ARL13B on breast cancer cell migration and
invasion through cytoskeleton-related mechanisms [41]. In familial breast cancer and CM,
ARL11 was suggested as a low-penetrance tumor suppressor gene [42,43]. To the best our
knowledge, this is the only study exploring the role of an ARL gene in CM. Considering
the multiplicity of physiological processes in which ARL proteins are involved, and their
impact on the growth and metastatic ability of several types of cancer, it is likely that they
play important roles in CM tumorigenesis and progression [26]. However, the role of these
proteins in cancer remains poorly explored, and specifically in CM, there are almost no data
about the relevance of ARL GTPases. Thus, it is essential to understand their usefulness as
potential biomarkers.
As far as we know, this is the first study based on integrated bioinformatics anal-
ysis to investigate the expression profile of ARL genes in primary and metastatic CM,
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their potential prognostic value, and biological roles in CM. Moreover, to identify the
mechanisms by which ARL expression affects the survival rates of CM patients, we also
assessed their influence on the immune microenvironment. Protein–protein interaction
(PPI) networks were generated to identify important players whose interaction with ARLs
could potentially affect CM prognosis. The bioinformatics analysis performed shows that
ARLs are differentially expressed in primary and metastatic CM, which could be related
to regulatory epigenetic mechanisms such as promoter methylation levels. Additionally,
the survival analyses performed demonstrate that ARL1, ARL11, and ARL15 expression
represent independent prognostic factors in CM. Interestingly, ARL11 seems to be the prog-
nostic factor with the most predominant impact on immune microenvironment remodeling
and on the recruitment and activation of immune cells. Therefore, our systematic analysis
provides an integrated understanding of ARL1, ARL11, and ARL15 function in CM and
their usefulness as potential biomarkers for the prognosis of CM patients.
2. Results
2.1. ARL Genes Are Differentially Expressed in Primary and Metastatic CM
Considering the lack of data on ARL function in CM, we evaluated their transcriptional
levels in primary and metastatic CM samples using the Cancer Genome Atlas (TCGA)
and Genotype tissue expression (GTEx) data, obtained from the University of California,
Santa Cruz (UCSC) Xena project and processed using a uniform bioinformatic pipeline.
The clinical characterization of patients with primary and metastatic CM is represented in
Table S1. A detailed workflow of the study design is shown in Figure 1.




Figure 1. Study design and workflow of the integrated bioinformatics analysis used to evaluate ARL 
function in CM. Expression data were downloaded from the UCSC Xena project, which provides 
RNA sequencing data obtained from the TCGA and GTEx databases. ARL expression analyses were 
performed using TCGA and GTEx data, as well as Gene Expression Profiling Interactive Analysis 
(GEPIA) web server. Genomic analyses of ARL genes were implemented using cBioPortal. Gene 
functional enrichment analyses were accomplished using the Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID), PANTHER 14.0, and g:Profiler software. Clinical data 
available on the TCGA database, OncoLnc, and GEPIA were used to perform the survival analyses 
included in this study. Immune-microenvironment relationship with ARL expression was estimated 
using Tumor Immune Estimation Resource (TIMER 2.0), and the Search Tool for the Retrieval of 
Interacting Genes (STRING) was also applied to discover ARL protein interaction networks. 
This analysis demonstrated that all 22 ARLs are differentially expressed in CM sam-
ples, as compared to normal skin tissue (Figure 2). ARL1, ARL2, ARL8A, and ARL11 are 
significantly upregulated in primary and metastatic CM samples, while ARL3, ARL4A, 
ARL4C, ARL4D, ARL5A, ARL5B, ARL5C, ARL8B, ARL9, ARL10, ARL13A, ARL13B, ARL15, 
ARL17A, and ARL17B are downregulated (Figure 2). Interestingly, ARL6 and ARL13B ex-
pression is significantly higher in metastatic CM, whereas ARL14 and ARL16 expression 
is decreased, suggesting their specific dysregulation in this stage of CM. 
ARL expression was also evaluated by tumor staging (I–IV) using the GEPIA plat-
form. This analysis validated the TCGA results, as no statistically significant differences 
were found in ARL3, ARL8B, ARL9, ARL13A, ARL17A or ARL17B expression between pri-
mary and metastatic CM (Figure S1). In addition, GEPIA analysis also showed that 
ARL5A, ARL5B, ARL6, ARL8A, ARL10, and ARL14 expression is not correlated with SKCM 
pathological stages. The differences in these two subsets of analysis could be related to 
the statistical tests performed. 
Figure 1. Study design and workflow of the integrated bioinformatics analysis used to evaluate ARL
function in CM. Expression data were downloaded from the UCSC Xena project, which provides
RNA sequencing data obtained from the TCGA and GTEx databases. ARL expression analyses were
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performed using TCGA and GTEx data, as well as Gene Expression Profiling Interactive Analysis
(GEPIA) web server. Genomic analyses of ARL genes were implemented using cBioPortal. Gene
functional enrichment analyses were accomplished using the Database for Annotation, Visualization
and Integrated Discovery (DAVID), PANTHER 14.0, and g:Profiler software. Clinical data available
on the TCGA database, OncoLnc, and GEPIA were used to perform the survival analyses included in
this study. Immune-microenvironment relationship with ARL expression was estimated using Tumor
Immune Estimation Resource (TIMER 2.0), and the Search Tool for the Retrieval of Interacting Genes
(STRING) was also applied to discover ARL protein interaction networks.
This analysis demonstrated that all 22 ARLs are differentially expressed in CM sam-
ples, as compared to normal skin tissue (Figure 2). ARL1, ARL2, ARL8A, and ARL11 are
significantly upregulated in primary and metastatic CM samples, while ARL3, ARL4A,
ARL4C, ARL4D, ARL5A, ARL5B, ARL5C, ARL8B, ARL9, ARL10, ARL13A, ARL13B, ARL15,
ARL17A, and ARL17B are downregulated (Figure 2). Interestingly, ARL6 and ARL13B
expression is significantly higher in metastatic CM, whereas ARL14 and ARL16 expression
is decreased, suggesting their specific dysregulation in this stage of CM.




Figure 2. Transcriptional levels of the 22 ARL genes expressed in the human genome and identified in primary (PM) and 
metastatic (MM) melanoma samples, obtained from TCGA, were compared to their levels in normal skin tissue (NT) ex-
tracted from the GTEx database after being processed using a uniform bioinformatics pipeline. The Kruskal–Wallis tests 
with post hoc Dunn’s method were performed for multiple comparisons. All tests were two-sided, with a significance 
level of 5%. Graphical representations were performed using GraphPad Prism 8.4.3. * p < 0.05; ** p < 0.01; *** p < 0.001; **** 
p < 0.0001. 
2.2. Promoter Methylation Levels May Influence the Expression of Some ARL Genes 
Then, we verified whether the dysregulation of these 22 genes in CM could be related 
to their mutational rate or the presence of copy number variations, using cBioPortal. Sur-
prisingly, these genes present a reduced mutational frequency ranging from 0% to 1.6% 
(Figure S2). ARL11 (1.6%) and ARL16 (1.6%) are the two most frequently mutated genes 
among the group evaluated (Figure S2). It is important to highlight that all the variants 
identified in these genes were reported as mutations in cBioPortal, although their patho-
genicity was not determined yet. 
Figure 2. Transcriptional levels of the 22 ARL genes expressed in the human genome and identified in primary (PM) and
metastatic (MM) melanoma samples, o t i ed from TCGA, were compared to their levels in normal skin tissue (NT)
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extracted from the GTEx database after being processed using a uniform bioinformatics pipeline. The Kruskal–Wallis tests
with post hoc Dunn’s method were performed for multiple comparisons. All tests were two-sided, with a significance
level of 5%. Graphical representations were performed using GraphPad Prism 8.4.3. * p < 0.05; ** p < 0.01; *** p < 0.001;
**** p < 0.0001.
ARL expression was also evaluated by tumor staging (I–IV) using the GEPIA plat-
form. This analysis validated the TCGA results, as no statistically significant differences
were found in ARL3, ARL8B, ARL9, ARL13A, ARL17A or ARL17B expression between
primary and metastatic CM (Figure S1). In addition, GEPIA analysis also showed that
ARL5A, ARL5B, ARL6, ARL8A, ARL10, and ARL14 expression is not correlated with SKCM
pathological stages. The differences in these two subsets of analysis could be related to the
statistical tests performed.
2.2. Promoter Methylation Levels May Influence the Expression of Some ARL Genes
Then, we verified whether the dysregulation of these 22 genes in CM could be related
to their mutational rate or the presence of copy number variations, using cBioPortal.
Surprisingly, these genes present a reduced mutational frequency ranging from 0% to
1.6% (Figure S2). ARL11 (1.6%) and ARL16 (1.6%) are the two most frequently mutated
genes among the group evaluated (Figure S2). It is important to highlight that all the
variants identified in these genes were reported as mutations in cBioPortal, although their
pathogenicity was not determined yet.
Similarly, the presence of copy number variations in ARL genes is not common in CM
samples (Figure S3). From the 367 samples assessed, 5% (19/367) contain amplifications
in ARL8A, 3% (11/367) amplifications and deletions in ARL2, and 5% (18/367) present
amplifications in ARL16 (Figure S3). Additionally, promoter methylation analysis using the
UALCAN tool demonstrated that ARL3, ARL5A, ARL9, ARL13A, ARL15, ARL16, ARL17A,
and ARL17B present higher β-values in metastatic CM samples compared to their levels
in normal tissue (Figure S4). These results suggest that the downregulation of these
genes in metastatic CM samples could be related to epigenetic regulatory mechanisms.
Despite the referred differences, the few genes presenting β-values ranging from 0.5 to 0.7,
and thus considered hypermethylated, were ARL4C, ARL5C, ARL9, ARL11, and ARL13A
(Figure S4). From these genes, all of them, except ARL11, were found downregulated in CM.
Accordingly, these data-driven results suggest that the mutational rate and copy number
variation status are not responsible for ARL dysregulation in CM. However, for some of
these genes, epigenetic mechanisms, such as promoter methylation, may be implicated in
the regulation of their expression in CM.
2.3. ARL GTPases Are Implicated in Cell Communication, Vesicle Transport, and Protein
Recruitment in CM
Since we found that ARLs are differentially expressed in CM, we further investigated
their involvement in relevant pathways related to cancer biology by employing gene
ontology analyses. Importantly, ARL genes were found enriched in biological processes
related to GTPase-mediated signaling transduction: cell communication; cellular response
to stimuli; protein recruitment to the cilium; organelle, membrane, and vesicle-mediated
transport; and intracellular protein transport (Figures 3A,C and S5). Functionally, ARLs
revealed an enrichment in processes related to α-tubulin binding, GTP binding, GTPase,
and pyrophosphatase activity (Figure 3B,D).
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Figure 3. Gene ontology and biological pathway functional enrichment analyses of ARL genes using DAVID and PANTHER
14.0 against a Homo sapiens background reference. Biological processes (A) and molecular functions (B) enriched for ARL
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2.4. ARL1, ARL11, and ARL15 Expression Represent Prognostic Factors in CM
To unveil whether ARLs dysregulation can provide essential clinical insights, we
explored their relevance in the prognosis of CM patients. Using clinical data of CM patients
accessed from the TCGA database, we performed a survival analysis employing overall
survival as the primary endpoint. From the 22 genes analyzed, only ARL1, ARL3, ARL5B,
ARL8A, ARL10, ARL11, ARL13A, ARL15, and ARL16 were found to have prognosis value
in the univariable analysis (Figures 4 and S6). Next, the Cox regression hazard model was
performed using the following confounder variables: age, gender, tumor stage, type of
tumor (primary/metastatic), and presence/absence of BRAF, NRAS, and NF1 mutations.
From the previous 9 genes with prognosis value in the univariable analysis, only 5 (ARL1,
ARL3, ARL10, ARL13A and ARL15) correspond to independent prognostic factors for CM
based on TCGA data (Tables S2–S10). An additional multivariable analysis performed
using the expression of all ARL genes as confounding variables, in addition to the variables
previously referred to, revealed that ARL1 and ARL15 are the only genes correlated with the
overall survival of CM patients, emphasizing their relevance to CM prognosis (Table 1). The
high ARL1 expression group was found to exhibit a prolonged overall survival compared
to the low ARL1 expression group, while the low ARL15 expression group is associated
with a favorable prognosis.




Figure 4. ARL prognostic value in CM patients assessed using TCGA clinical data. The results presented show exclusively 
the ARL genes whose expression is significantly correlated with CM patients’ overall survival. The Kaplan–Meier survival 
curves with higher (green) and lower (blue) ARL expression than the median expression found in normal skin tissue were 
generated using IBM SPSS Statistics 21.0. Differences in the overall survival of CM patients were identified by employing 
the log-rank test. p < 0.05 was considered statistically significant. 
Table 1. Multivariable analysis of ARL expression for the overall survival of CM patients available 
on TCGA. 
Variables  p-Value Exp(B) 
95.0% CI for Exp(B) 
Lower Upper 
ARL1 0.022 1.642 1.074 2.510 
ARL2 0.436 1.805 0.408 7.980 
ARL3 0.094 2.873 0.835 9.882 
ARL4A 0.120 3.565 0.718 17.705 
ARL4C 0.211 0.675 0.364 1.250 
ARL4D 0.952 0.956 0.219 4.163 
ARL5A 0.561 0.814 0.407 1.628 
ARL5B 0.513 1.645 0.371 7.306 
ARL5C 0.720 0.850 0.351 2.063 
Figure 4. ARL prognostic value in CM patients assessed using TCGA clinical data. The results presented show exclusively
the ARL genes whose expression is significantly correlated with CM patients’ overall survival. The Kaplan–Meier survival
curves ith higher (green) and lo er (blue) ARL expression than the edian expression found in nor al skin tissue ere
i i i . . i i ll i l i i ifi l i
l - t t. fi
Table 1. ultivariable analysis of ARL expression for the overall survival of C patients available
on TCGA.
Variables p-Value Exp(B)
95.0% CI for Exp(B)
Lower Upper
ARL1 0.022 1.642 1.074 2.510
ARL2 0.436 1.805 0.408 7.980
ARL3 0.094 2.873 0.835 9.882
L4A 0.120 3.565 0.718 17.70
4C 0.211 0.675 0.364 1.250
ARL4D 0.952 0.956 0.219 4.163
ARL5A 0.561 0.814 0.407 1.628
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Table 1. Cont.
Variables p-Value Exp(B)
95.0% CI for Exp(B)
Lower Upper
ARL5B 0.513 1.645 0.371 7.306
ARL5C 0.720 0.850 0.351 2.063
ARL6 0.149 3.268 0.655 16.312
ARL8A 0.912 0.955 0.424 2.151
ARL8B 0.136 2.144 0.787 5.837
ARL9 0.194 4.025 0.492 32.914
ARL10 0.413 0.632 0.211 1.895
ARL11 0.953 1.080 0.083 14.113
ARL13A 0.343 0.561 0.169 1.855
ARL13B 0.537 0.801 0.395 1.621
ARL14 0.818 0.823 0.157 4.312
ARL15 0.009 0.288 0.114 0.730
ARL16 0.719 1.243 0.380 4.074
ARL17A 0.873 0.801 0.053 12.167
ARL17B 0.455 0.395 0.035 4.514
Age 0.000 1.023 1.013 1.034
Gender 0.691 1.070 0.767 1.491
Tumor Grade 0.000 0.200 0.096 0.417
Type of Tumor 0.840 1.239 0.154 9.941
BRAF mutations 0.792 1.050 0.732 1.504
NRAS mutations 0.402 0.851 0.583 1.242
NF1 mutations 0.488 1.194 0.723 1.972
Among all candidates, GEPIA and OncoLnc survival tools also show that a higher
expression of ARL11 is significantly associated with an improved prognosis of CM pa-
tients, agreeing with the survival analysis performed using TCGA data (Figures S7 and
S8). Although ARL11 is not an independent prognostic factor according to TCGA data,
ARL11 expression has independent prognosis value based on GEPIA and OncoLnc results.
Hence, ARL11 expression should also be considered a potential candidate with impact on
CM prognosis. Altogether, these results highlight the role of ARL1, ARL11, and ARL15
expression as important players in CM patient prognosis.
2.5. ARL11 May Have a Predominant Impact on Immune Microenvironment Remodeling
Since CM is a highly immunogenic type of tumor, after discovering that ARL1, ARL11,
and ARL15 expression may have a significant impact on CM patients’ prognosis, we
investigated whether the immune microenvironment could be involved in the mechanisms
associated with ARL prognostic value. For this purpose, the relationships between ARL
expression and immune infiltrate levels in SKCM, SKCM-primary, and SKCM-metastasis
datasets were determined.
The integrative analysis of TIMER results showed that there is a significant general cor-
relation between neutrophils, CD4+ T cells, and common lymphoid progenitor infiltration
and ARL1, ARL3, ARL4A, ARL4C, ARL5A, ARL5B, ARL11, ARL13B, and ARL15 expression.
This suggests the existence of an immune signature characteristic of CM cells expressing
these genes (Figures S9–S12). Therefore, when analyzing the significant correlations be-
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tween all ARL genes and immune cell infiltrates, we discovered a common CM immune
profile, which may be connected or even enhanced by ARL expression (Figures S9–S12).
Specifically, we observed that ARL1 expression is negatively correlated with CD4+ Th1
cells (Cor = −0.601) and positively correlated with CD4+ Th2 cells (Cor = 0.598), neutrophils
(Cor = 0.501), and common lymphoid progenitor cells (Cor = 0.720) in SKCM, being these
correlations stronger in the SKCM-primary subset (Figures 5A and S10).




Figure 5. Spearman’s correlation coefficients calculated between immune cell infiltrates and ARL1 (A), ARL11 (B), and 
ARL15 (C) expression in SKCM (n = 471), SKCM-primary, (n = 103) and SKCM-metastasis (n = 368) datasets. Data were 
obtained from the TIMER 2.0 platform and represented using heat maps. All the correlations indicated are statistically 
significant. Green is associated with weaker correlation coefficients, while red is indicative of stronger correlations. Cor-
relations were determined using the purity adjustment definition and only genes with Spearman coefficient >0.4 were 
considered positively correlated. 
Interestingly, we found that ARL11 expression is correlated with 17 out of the 21 im-
mune infiltrates available on TIMER in either SKCM, SKCM-primary, or SKCM-metasta-
sis datasets (Figure 5B and Figure S9). For instance, ARL11 expression is positively corre-
lated with CD8+ T cell infiltration (Cor = 0.576), using five distinct algorithms from the 
TIMER platform in SKCM samples, but particularly in the SKCM-metastasis subset (Table 
S11). Furthermore, specific positive correlations were identified with CD8+ memory T cells 
(Cor = 0.572), CD4+ memory T cells (Cor = 0.602), neutrophils (Cor = 0.697), macrophages 
(Cor = 0.603), M1 macrophages (Cor = 0.662), M2 macrophages (Cor = 0.739), monocytes 
(Cor = 0.842), myeloid dendritic cells (Cor = 0.624), myeloid dendritic cells activated (Cor 
= 0.612), plasmocytoid dendritic cells (Cor = 0.496), NK cells (Cor = 0.546), NK cells acti-
vated (Cor = 0.467), T cell follicular helper (Cor = 0.508), B cells (Cor = 0.498), and memory 
B cells (Cor = 0.463), using more than one algorithm for the majority of these immune 
subsets (Table S11). All the correlations highlighted are statistically significant. Based on 
these results, ARL11 expression seems to be the prognostic factor with the most predomi-
nant function in immune microenvironment remodeling. Similarly to ARL1, ARL15 ex-
pression is also negatively correlated with CD4+ Th1 cells (Cor = −0.506) and NK cells (Cor 
= −0.541) in the SKCM-primary dataset, while positively correlated with CD4+ T cells (Cor 
Figure 5. rrelation coefficients calculated between immune c ll infiltrates and ARL1 (A), ARL11 (B), and ARL15
(C) expression in SKCM (n = 471), SKCM-primary, (n = 103) and SKCM-metastasis (n = 368) datasets. Data were obtained
from the TIMER 2.0 platform and represented using heat maps. All the correlations indicated are statistically significant.
Green is associated with weaker correlation coefficients, while red is indicative of stronger correlations. Correlations
were determined using the purity adjustment definition and only genes with Spearman coefficient >0.4 were considered
positively correlated.
Interestingly, we found that ARL11 expression is correlated with 17 out of the 21 im-
mune infiltrates available on TIMER in either SKCM, SKCM-primary, or SKCM-metastasis
datasets (Figures 5B and S9). For instance, ARL11 expression is positively correlated
with CD8+ T cell infiltration (Cor = 0.576), using five distinct algorithms from the TIMER
platform in SKCM samples, but particularly in the SKCM-metastasis subset (Table S11).
Furthermore, specific positive correlations were identified with CD8+ memory T cells
(Cor = 0.572), CD4+ memory T cells (Cor = 0.602), neutrophils (Cor = 0.697), macrophages
(Cor = 0.603), M1 macrophages (Cor = 0.662), 2 acrophages (Cor = 0.739), onocytes
(Cor = 0.842), myeloid dendritic cells (Cor = 0.624), myeloid dendritic cells activated
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(Cor = 0.612), plasmocytoid dendritic cells (Cor = 0.496), NK cells (Cor = 0.546), NK cells
activated (Cor = 0.467), T cell follicular helper (Cor = 0.508), B cells (Cor = 0.498), and
memory B cells (Cor = 0.463), using more than one algorithm for the majority of these
immune subsets (Table S11). All the correlations highlighted are statistically significant.
Based on these results, ARL11 expression seems to be the prognostic factor with the most
predominant function in immune microenvironment remodeling. Similarly to ARL1, ARL15
expression is also negatively correlated with CD4+ Th1 cells (Cor = −0.506) and NK cells
(Cor = −0.541) in the SKCM-primary dataset, while positively correlated with CD4+ T
cells (Cor = 0.431), neutrophils (Cor = 0.559), and macrophages M2 (Cor = 0.504) in SKCM
(Figures 5C and S10).
2.6. ARL11 Is Closely Interconnected with Proteins Involved in Immune Cell Activation and Recruitment
Protein–protein interaction networks were generated through SPRING version 11
database, choosing the top 20 most related proteins to ARL1, ARL11, and ARL15. Accord-
ing to this analysis, ARL1 and ARL15 are mainly associated with proteins involved in
membrane trafficking and vesicular transport-related pathways (Figure 6A,C). The scores
of ARL1 interactions range between 0.921 and 0.998, while the ARL15-associated network
achieves scores between 0.6 and 0.7 (Figure 6A,C). Additionally, we found that ARL11 is
interconnected with a set of proteins such as ZAP70, interleukin-17 receptor D (IL17RD),
disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), Bcl-2-like pro-
tein 14 (BCL2L4), E3 ubiquitin-protein ligase (TRIM13), P2X purinoceptor 7 (P2Rx7), and
hypoxia-inducible factor 1-alpha inhibitor (HIF1AN) (scores from 0.5 to 0.7), all implicated
in cancer-related pathways (Figure 6B). Hence, these interactions highlight the involvement
of ARL11 in mechanisms implicated in innate and adaptive immune activation, caspase
activation, Ras-MAPK regulation, inflammation, and tumorigenesis.
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3. Discussion
Despite the remarkable efforts to improve our understanding of CM biology, there
is still a need to identify new biomarkers to further stratify patients based on prognosis,
metastatic propensity, and response to therapy [15]. Unfortunately, current knowledge
about ARF family members in CM is limited, and in particular, ARL proteins’ involvement
in CM etiology and progression remains unknown [26]. Hence, we evaluated the effect of
ARL expression in prognosis, immune microenvironment modification, and their functional
interactions with well-established signaling pathways in CM by performing an integrative
analysis of open access databases. The large number of candidates included in this GTPase
family led us, in a first stage, to perform a bioinformatics analysis to select the most
clinically and biologically relevant Arls to be studied using in vitro and in vivo assays.
Analysis of transcriptomes obtained from TCGA and GTEx revealed that 22 ARL genes
are differentially expressed in CM—4 upregulated and 14 downregulated in both primary
and metastatic CM samples—while the remaining 4 genes are only found dysregulated in
metastatic CM. Until now, no study has explored simultaneously the expression levels of
these 22 genes in a cancer context. Similar to what was observed in CM, ARL2 upregulation
was also described in bladder [32] and cervical [31] cancers, as well as in hepatocellular
carcinomas [44]. Furthermore, ARL3 downregulation was verified in glioma [45]. While in
CM ARL11 was found upregulated, compared to normal skin tissue, in breast, lung, ovarian
and prostate cancers, it was shown to be downregulated by DNA hypermethylation and
genomic deletions [43,46]. The studies mentioned above investigated the function of single
ARL genes. Hence, much remains to be known about the impact of the remaining ARL
candidates on these types of cancer. Considering the expression profiles obtained, we
hypothesized that ARLs may have essential functions during CM progression, probably
representing promising biomarkers to distinguish malignant stages.
To infer the main cause of ARL dysregulation in CM, we assessed the mutational rate
and copy number alterations of these genes, although these events are not responsible for
the differences identified in expression. Additionally, we evaluated promoter methylation
levels to understand whether epigenetic mechanisms could be related to ARL differential
expression. Despite the reduced number of skin samples (n = 2) included in the methylation
analysis, it seems that this epigenetic event can be involved in the transcriptional regulation
of these genes. Therefore, it is necessary to explore whether the ARL expression pattern is
associated with the effect of driver genes or is even due to alterations in specific chromatin
regulators, as previously described for other pathologies [47,48]. Further studies using
well-characterized cohorts will be crucial to validate whether this expression profile is
maintained at the protein level, providing relevant data for the clinical management of
CM patients.
Several studies have reported that dysregulation of ARL expression or activity can be
associated with enhanced cell migration, invasion, and proliferation in distinct types of
cancer [36,39–41,49]. Since gene ontology analyses demonstrated that ARLs are enriched
for pathways implicated in the response to stimuli, protein and vesicle transport, signaling
transduction, and cell communication, their involvement in CM cell migration and invasion
seems possible. Recently, vesicle trafficking pathways have emerged as key regulatory
elements in migration and invasion, with endocytosis and recycling of cell surface cargoes
being of major importance [50,51]. Thus, the role of ARL proteins in CM malignant
characteristics should be assessed using migration and invasion assays.
Although some well-established biomarkers have no impact on CM prognosis, we
decided to evaluate whether ARL genes could provide relevant knowledge about patients’
overall survival. Increased expression of ARL1 and ARL11 in CM is associated with a
favorable prognosis, while low expression of ARL15 is indicative of the poorest outcomes
according to the clinical data available on the TCGA database. Consistently, a previous
study proposed ARL11 as a tumor suppressor gene due to its ability to inhibit tumor
formation in immunodeficient mice after transfection with a lung cancer cell line [46].
Hence, the few available data on ARL11 function are consistent with the survival results
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presented, evidencing the pivotal role of this gene in patients’ outcome. However, the
functions of Arl11 and Arl15 under physiological conditions remain unknown.
Even though distinct factors influence CM occurrence and prognosis, immune re-
sponses are considered key factors owing to CM immunogenicity [52,53]. Additionally,
the relationship between specific molecular signatures and immune microenvironment
has been mentioned as contributing to tumor aggressiveness, consequently influencing
patients’ prognosis and response to therapy [54]. Nevertheless, no study has examined
the correlation between ARL expression and immune cell infiltration in CM. Hence, we
sought to better understand this relationship and how it might affect CM prognosis. For
instance, we verified that high ARL1 expression enhances neutrophil, CD4+ Th2 cell and
CLP infiltration, an immune profile that may be associated with an anti-tumoral effect,
which is consistent with its physiological role in immune activation. Recent studies have
shown the existence of a highly specific subset of neutrophils with an anti-tumoral activity
related to the production of extracellular traps that inhibit CM cell migration [55]. In fact,
neutrophils recruit and activate immune cells by producing a variety of chemical factors
to stimulate T cell proliferation, NK, and dendritic cell maturation [54]. Additionally, a
previous study also described that CD4+ Th2 cells can make the clearance of established
lung and visceral CM metastases by enhancing CD8+ T cell activation, while CD4+ Th1
cells have no effect on tumor growth [56]. Another important immune subset includes
CLP cells, which can differentiate into CD4+ Th cells, justifying why CLP and CD4+ Th2
cells are both correlated with ARL1 expression [57]. Thus, the integrative analysis of these
results leads us to hypothesize that ARL1 upregulation positively affects the infiltration of
these immune subsets, favoring an improved prognosis of CM patients.
In addition to ARL1, ARL11 is the most impactful gene contributing to CM immune
microenvironment remodeling through the recruitment of CD8+ T cells, CD4+ memory T
cells, macrophages, B cells, NK cells, neutrophils, and dendritic cells. Particularly, CD8+ T
cells and M2 macrophages, which are characterized by their beneficial anti-tumoral effect,
show very strong and reliable correlations with ARL11 expression. Recently, a study found
that peripheral CD8+ T cell characteristics are associated with more durable responses to
immune checkpoint blockade in patients with metastatic CM [58]. There is also evidence
showing that dendritic cells and some macrophages can prime adaptive immunity to incite
cytotoxicity of CD8+ effector T cells [59]. In the last 5 years, many reports have recognized
the critical role of CD4+ T cells in driving anti-tumor immunity and supporting anti-tumor
CD8+ T cell responses [60]. Furthermore, evidence of tumor-resident mature B cells and
reports of associations with favorable prognosis in malignant CM suggest that humoral
immunity participates in anti-tumor defense [61]. Altogether, these results indicate that
ARL11 upregulation has a positive impact in CM patients’ overall survival, in part by
inducing an immune profile relying on an anti-cancer activity to a greater extent compared
to ARL1 expression (Figure 7). However, given that there are few data about ARL function,
tissue expression needs to be more thoroughly profiled because this is a major confounding
factor in the analysis of immune cell infiltration in CM. Thus, the correlations between ARL
expression and immune cell infiltrates observed using the TIMER web server should be
further assessed using flow cytometry to ensure that these associations are specific of CM
cells. This way, we can truly ensure that ARL expression in CM cells is driving increased
infiltration of immune subsets and not that ARL are highly expressed in immune subsets
rather than in tumor cells, which would yield the same observed associations.
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and its interactions with proteins involved in pathways of immune cell activation and recruitment, po-
tentially associated with the mechanisms by which ARL11 expression improves CM patients’ prognosis.
The PPI analysis performed using the STRING database demonstrated the interac-
tion between ARL11 and several proteins involved in innate and adaptative immune
activation, corroborating the hypothesis that ARL11 is tightly interconnected with CM
immune microenvironment modulation. For instance, ARL11 was associated with ZAP70
(score = 0.5), a cytoplasmic tyrosine kinase that plays a critical role in the events involved
in initiating T cell responses by the antigen receptor [62]. Despite its controversial function,
P2RX7, a plasma membrane receptor for extracellular ATP that is expressed at a high
level by immune and tumor cells, also belongs to the PPI network of ARL11 (score = 0.7).
New evidence suggests that P2RX7 has an essential role in restraining tumor progres-
sion [63]. Moreover, in vitro studies have shown that IL17RD, another ARL11-related
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protein (score = 0.7), exerts inhibitory effects on MAPK signaling to restrain the prolifer-
ation of various cancer cell lines [64]. Genes associated with MAPK regulation, caspase
activation, and tumorigenesis are also part of the ARL11 interactive network, highlighting
its pivotal role in the regulation of immune and cancer-related pathways (Figure 7).
The integrated analysis of ARL15 expression, prognosis, and immune characterization
generated inconclusive data, because its correlation with immune cells is not sufficient to
elucidate the putative mechanism related to ARL15 prognosis value. However, the bioin-
formatics analysis performed highlighted the essential role of the tumor microenvironment
in the mechanisms related to the prognostic value of ARL1 expression but mostly ARL11
expression. Further studies are required to validate whether the interplay between ARL
expression and immune cell infiltration is truly reliable, ensuring the accuracy and clinical
relevance of these assumptions.
4. Conclusions
The understanding of CM biology is pivotal to gain insight about the mechanisms
involved in its progression and simultaneously on how to impair these processes. Overall,
this integrative in silico analysis suggests that ARL expression is highly dysregulated in
CM, highlighting their relevance in CM tumorigenesis and metastasis. Additionally, this
study underscores that ARL11 expression may improve CM patient prognosis, mainly
through the recruitment of immune infiltrates with anti-tumorigenic activity. Therefore,
our systematic analysis provides an integrated understanding of the potential functions of
ARL1, ARL11, and ARL15 in CM and their usefulness as biomarkers for the prognosis of
CM patients. Further functional studies are needed to verify the validity of these findings.
5. Materials and Methods
5.1. Study Design and Data Acquisition
A detailed workflow of our study design is shown in Figure 1. Illumina HiSeq 2000 RNA
sequencing data of CM and normal skin tissue samples from the Cancer Genome Atlas (TCGA)
and Genotype tissue expression (GTEx), respectively, were downloaded from the University of
California, Santa Cruz (UCSC) Xena project (http://xena.ucsc.edu) [65]. These datasets were
obtained from the TCGA TARGET GTEX study that includes samples re-analyzed by the same
RNA seq pipeline (https://xenabrowser.net/datapages/?dataset=TcgaTargetGtex_RSEM_
Hugo_norm_count&host=https%3A%2F%2Ftoil.xenahubs.net&removeHub=https%3A%2F%
2Fxena.treehouse.gi.ucsc.edu%3A443, accessed on September 2020). As all samples were
processed using a uniform bioinformatic pipeline, the batch effect due to different compu-
tational processing was eliminated. TCGA data and data from unrelated healthy tissues,
recomputing (RSEM, batch-normalized, log2(x + 1)-transformed), were downloaded from
the UCSC Xena. The TCGA-SKCM (skin cutaneous melanoma) dataset includes 102 pri-
mary and 366 metastatic CM samples, while the GTEx dataset contains 556 normal skin
samples from healthy donors.
5.2. Gene Expression and Promoter Methylation Analysis
ARL gene expression in primary, metastatic CM, and normal skin tissue samples
collected from TCGA and GTEx, respectively, was displayed in scatter plots performed
using GraphPad 8.0.1 software. Gene expression profiles across samples were compared
using non-parametric tests, namely the Kruskal–Wallis test with post-hoc Dunn’s method
for multiple comparisons. The Gene Expression Profiling Interactive Analysis (GEPIA)
database was also used to compare the expression of the 22 ARL genes in CM samples and
their normal tissue counterparts, as well as their expression in distinct CM TNM stages
(http://gepia2.cancer-pku.cn/) [66]. This differential expression analysis was transformed
in log2 (transcripts per kilobase million + 1), and one-way ANOVA was used for group
comparison [67].
To assess whether differences found in ARL expression could be related to promoter
methylation levels, the UALCAN online tool was used. Therefore, it was used to perform
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a comprehensive analysis of promoter DNA methylation patterns in normal skin tissue
(n = 2), primary (n = 104), and metastatic CM (n = 368) samples. The β-value indicates the
level of DNA methylation, ranging from 0 (unmethylated) to 1 (methylated). In this study,
β-values ranging from 0.5 to 0.7 indicate hyper-methylation while β-values from 0.25 to
0.3 are suggestive of hypo-methylation [68].
5.3. Genomic Analysis
To determine the mutational profile and copy number variation status of ARL genes,
367 CM samples from SKCM (TCGA, Firehose Legacy) datasets were uploaded from the
cBioportal platform (http://www.cbioportal.org) [69]. In this analysis, we included trunca-
tions, missense, and splice mutations (frequency ≤ 1) with unknown clinical significance
in CM. The pathogenic effects of these alterations have not been tested yet. The same was
verified for amplification and deletions found in these genes.
5.4. Gene Ontology Enrichment Analysis
ARL expression was subjected to gene ontology (GO) and biological pathway en-
richment analyses to elucidate their related biological processes and molecular functions
using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (https:
//david.ncifcrf.gov/summary.jsp) [70], PANTHER 14.0 (http://pantherdb.org) [71,72]
and g:Profiler (https://biit.cs.ut.ee) [73] against a Homo sapiens background reference. Al-
though all three tools use very similar statistical algorithms in the back end, there are
some differences among them. In fact, DAVID downloads PANTHER data and integrates
them in its analysis tools. The statistical over-representation was calculated using the
binomial test of PANTHER 14.0 and the results were considered significant at p < 0.05,
after Bonferroni correction. The binomial test is employed to determine whether there is a
statistical over-representation of genes in the test list compared to the reference list. This
statistical test evaluates whether a specific functional class of genes appears statistically
more often in the input list than expected. In the over-representation test, p-values were
adjusted by default using the Bonferroni correction for multiple testing performed on the
PANTHER 14.0 site.
5.5. Survival Analysis
Survival data from CM patients were obtained from TCGA, and patients with unavail-
able clinical information were excluded from this analysis. The correlation between gene
expression and overall survival was estimated using the Kaplan–Meier curves and the log-
rank test. The Kaplan—Meier curves were performed using the median expression of each
ARL gene in normal skin samples as the cutoff to define the groups of CM patients with a
high or low ARL mRNA expression. The expression thresholds used for each ARL gene are
shown in Table S12. Variables with a significant p-value in the univariable analysis were
exposed to a multivariable analysis using the Cox regression proportional hazard model.
The multivariable analysis included the following confounder variables: age, gender, tumor
grade, type of tumor (primary/metastatic), v-Raf murine sarcoma viral oncogene homolog
B1 (BRAF), neuroblastoma RAS viral oncogene homolog (NRAS) and neurofibromatosis
type 1 (NF1) mutations and the expression of other ARL genes. The ARL prognostic value
was also assessed using two online survival tools: OncoLnc (http://www.oncolnc.org) and
GEPIA [66,74]. In the latter analyses, patients were divided into non-overlapping groups
according to the median expression of these genes in CM samples defined using these
specific web servers.
5.6. Tumor Microenvironment Characterization
The correlation between ARL expression and immune cell infiltration was determined
using the Tumor Immune Estimation Resource (TIMER) 2.0 server (http://timer.cistrome.
org/) [75]. The TIMER platform is frequently used to study the relationship between cancer
and immune cell infiltration using several algorithms available for each immune subset.
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The correlation of ARL gene expression with several immune cell infiltrates such as CD8+
T lymphocytes, CD4+ T lymphocytes, regulatory T cells (Treg), B lymphocytes, neutrophils,
monocytes, macrophages, dendritic cells, microglia, Natural Killer (NK) cells, mast cells,
cancer-associated fibroblasts, common lymphoid progenitor, common myeloid progenitor,
endothelial cell, eosinophil, granulocyte-monocyte progenitor, hematopoietic stem cell, T
cell follicular helper, T cell gamma delta, NK T cell, and myeloid-derived suppressor cell
tumor was displayed. The correlations between all these immune infiltrate levels and the
expression of the 22 ARL genes were performed in 3 distinct subsets: SKCM samples, SKCM
primary samples, and SKCM-metastatic samples. All these correlations were calculated
using the purity (percentage of malignant cells in a tumor tissue) adjustment definition
and Spearman’s correlation coefficient. Tumor purity is a major confounding factor in
this analysis, since most immune cell types are negatively correlated with tumor purity.
Therefore, we selected the “Purity Adjustment” option. Genes highly expressed in cells in
the microenvironment are expected to have negative associations with tumor purity, while
the opposite is expected for genes highly expressed in the tumor cells. Only genes with
Spearman’s coefficient <0.4 were considered positively correlated.
5.7. Protein–Protein Interaction (PPI) Network Analysis
The Search Tool for the Retrieval of Interacting Genes (STRING) (https://string-
db.org/) [76] was the database employed to predict ARL functional interactions and
their crosstalk with well-known annotated signaling pathways. PPI presents a score that
indicates the confidence in the interactions proposed based on the available evidence. This
score ranges from 0 to 1, with 1 being the highest possible confidence. Proteins with a
score of ≥0.4 were included in the network models visualized. Additionally, the proteins
included in PPI networks were divided into a color pattern to distinguish them based
on their involvement in specific pathways such as membrane trafficking and vesicular
transport, cancer-related pathways, and others.
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